Aytu Biopharma Inc
NASDAQ:AYTU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
MTQ Corporation Ltd
SGX:M05
|
SG |
|
C
|
Cryptoblox Technologies Inc
CNSX:BLOX
|
CA |
|
U
|
United Internet AG
XHAM:UTDI
|
DE |
|
D
|
Deleum Bhd
KLSE:DELEUM
|
MY |
|
Solvac SA
XBRU:SOLV
|
BE |
|
Cnova NV
PAR:CNV
|
NL |
|
H & R Block Inc
NYSE:HRB
|
US |
|
Farmers And Merchants Bank of Long Beach
OTC:FMBL
|
US |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Aytu Biopharma Inc
NASDAQ:AYTU
|
28m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Aytu Biopharma Inc
Glance View
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Englewood, Colorado and currently employs 175 full-time employees. The company went IPO on 2017-10-20. The firm markets a portfolio of prescription products addressing primary care and pediatric markets. The firm's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. The company markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The firm's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Aytu Biopharma Inc is 66.8%, which is above its 3-year median of 66.4%.
Over the last 3 years, Aytu Biopharma Inc’s Gross Margin has increased from 59.5% to 66.8%. During this period, it reached a low of 59.5% on Dec 31, 2022 and a high of 75.3% on Jun 30, 2024.
